187 related articles for article (PubMed ID: 31478526)
1. Severe Maculopapular Exanthema Induced by Regorafenib: Successful Desensitization and Adaptation of a Dosage Regimen.
García-Gutiérrez I; Acevedo M; Tornero P; Matilla A; Márquez L; Sánchez-Herrero A; Prieto-García A
J Investig Allergol Clin Immunol; 2019 Aug; 29(4):300-302. PubMed ID: 31478526
[No Abstract] [Full Text] [Related]
2. Regorafenib: A Review in Hepatocellular Carcinoma.
Heo YA; Syed YY
Drugs; 2018 Jun; 78(9):951-958. PubMed ID: 29915898
[TBL] [Abstract][Full Text] [Related]
3. Oral "desensitization" of maculopapular exanthema from ciprofloxacin.
Bircher AJ; Rutishauser M
Allergy; 1997 Dec; 52(12):1246-8. PubMed ID: 9450149
[No Abstract] [Full Text] [Related]
4. Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma.
Naruto K; Kawaoka T; Amioka K; Ogawa Y; Chihiro K; Yoshikawa Y; Ando Y; Suehiro Y; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Murakami E; Nakahara T; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Takaki S; Mori N; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Kohno H; Kohno H; Moriya T; Naeshiro N; Azakami T; Imamura M; Chayama K; Aikata H
Oncology; 2021; 99(8):491-498. PubMed ID: 34000725
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib-Associated Fatigue: A Systematic Review and Meta-analysis.
Invally M; Kanukula R; Salam MA; Shruthi G
Am J Ther; 2018; 25(6):e715-e717. PubMed ID: 29465445
[No Abstract] [Full Text] [Related]
6. Regorafenib: a newly approved drug for advanced hepatocellular carcinoma.
Kyrochristos ID; Ziogas DE; Roukos DH
Future Oncol; 2017 Aug; 13(19):1665-1668. PubMed ID: 28613123
[No Abstract] [Full Text] [Related]
7. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib-induced hand-foot skin reaction with striking epidermal dysmaturation - a new histopathological pattern associated with the use of multi-kinase inhibitors.
Llamas-Velasco M; Hegyi I; Hesterberg U; Daudén E; Requena L; Kempf W
Br J Dermatol; 2016 Jul; 175(1):216-7. PubMed ID: 26801207
[No Abstract] [Full Text] [Related]
9. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
[No Abstract] [Full Text] [Related]
10. [Adverse effects of new oncologic therapies].
Weisshaupt Ch; Budak K; Pestalozzi B
Praxis (Bern 1994); 2011 Jul; 100(15):885-91; quiz 890. PubMed ID: 21792802
[No Abstract] [Full Text] [Related]
11. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.
Jones RL; Bendell JC; Smith DC; Diefenbach K; Lettieri J; Boix O; Lockhart AC; O'Bryant C; Moore KN
Cancer Chemother Pharmacol; 2015 Oct; 76(4):777-84. PubMed ID: 26281907
[TBL] [Abstract][Full Text] [Related]
12. Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature.
Park MA; Volcheck GW; Guarderas JC
Allergy Asthma Proc; 2004; 25(5):345-7. PubMed ID: 15603208
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib-induced eruption resembling pityriasis rubra pilaris.
Paz C; Querfeld C; Shea CR
J Am Acad Dermatol; 2011 Aug; 65(2):452-453. PubMed ID: 21763585
[No Abstract] [Full Text] [Related]
14. Regorafenib Also Can Cause Osteonecrosis of the Jaw.
Antonuzzo L; Lunghi A; Giommoni E; Brugia M; Di Costanzo F
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26857267
[No Abstract] [Full Text] [Related]
15. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
Shirasawa M; Kubotaa M; Harada S; Niwa H; Kusuhara S; Kasajima M; Hiyoshi Y; Ishihara M; Igawa S; Masuda N
Lung Cancer; 2016 Sep; 99():66-8. PubMed ID: 27565916
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib in the treatment of metastatic colorectal cancer.
de la Fouchardière C
Future Oncol; 2018 Sep; 14(22):2239-2246. PubMed ID: 29569472
[TBL] [Abstract][Full Text] [Related]
17. Regorafenib: start low and go slow.
Tabchi S; Ghosn M
Target Oncol; 2015 Sep; 10(3):445-7. PubMed ID: 25548130
[No Abstract] [Full Text] [Related]
18. Single dose regorafenib-induced hypertensive crisis.
Yilmaz B; Kemal Y; Teker F; Kut E; Demirag G; Yucel I
Exp Oncol; 2014 Jun; 36(2):134-5. PubMed ID: 24980770
[TBL] [Abstract][Full Text] [Related]
19. Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib.
Kongsuphon N; Soukavanitch M; Teeraaumpornpunt N; Konmun J; Ativitavas T; Ngamphaiboon N
J Gastrointest Cancer; 2019 Sep; 50(3):601-603. PubMed ID: 29411249
[No Abstract] [Full Text] [Related]
20. [Regorafenib approved in Metastatic Colorectal cancer].
André T; Dumont SN
Bull Cancer; 2013 Oct; 100(10):1027-9. PubMed ID: 24047557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]